propafenone eg 150mg film-coated tablets
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - propafenone hydrochloride - film-coated tablet - propafenone hydrochloride 150 mg - cardiac therapy
propafenone 300mg tablets
medihealth (northern) ltd - propafenone hydrochloride - oral tablet - 300mg
rytmonorm 150mg tab 150 mg
مستودع ادوية السختيان - sukhtian group - propafenone hcl 150 mg - 150 mg
rytmonorm 300mg tab 300 mg
مستودع ادوية السختيان - sukhtian group - propafenone hcl 300 mg - 300 mg
rytmonorm 150mg tab 150 mg
مستودع ادوية السختيان - sukhtian group - propafenone hcl 150 mg - 150 mg
rytmonorm 300mg tab 300 mg
مستودع ادوية السختيان - sukhtian group - propafenone hcl 300 mg - 300 mg
arythmol sr
abbott laboratories ireland ltd - propafenone hydrochloride - prolonged release capsules - 225 milligram
arythmol sr
abbott laboratories ireland ltd - propafenone hydrochloride - prolonged release capsules - 325 milligram
arythmol sr
abbott laboratories ireland ltd - propafenone hydrochloride - prolonged release capsules - 425 milligram
rytmonorm
viatris limited - propafenone hydrochloride 150mg; ; ; propafenone hydrochloride 150mg - tablet - 150 mg - active: propafenone hydrochloride 150mg excipient: croscarmellose sodium hypromellose macrogol 400 macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide active: propafenone hydrochloride 150mg excipient: croscarmellose sodium hypromellose macrogol 400 macrogol 6000 magnesium stearate microcrystalline cellulose pregelatinised maize starch purified water titanium dioxide - for the treatment of supraventricular extrasystoles and supraventricular tachycardias, and in wolff-parkinson-white (wpw) syndrome. also for the treatment of life-threatening documented ventricular tachyarrhythmia. the use of rytmonorm is not recommended in patients with less severe ventricular arrhythmias, even if the patients are symptomatic. because of the proarrhythimic effects of rytmonorm, its use should be reserved for patients in whom, in the opinion of the physician, the potential benefits of treatment outweigh the risks.